Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

What was studied

This trial tested long-acting antibodies against HIV. The antibodies were 3BNC117-LS and 10-1074-LS. Adults aged 18-60 years took part. They began HIV drugs early in infection. 68 people were put by chance on the antibodies or on saline placebo. 34 were in each group. Then they stopped their HIV drugs, called ART. The main aim was time to viral rebound.

What they found

By week 20, 30 people on placebo had viral rebound. Rebound was far less common in the antibody group. The hazard ratio was 0·09, with a range of 0·04-0·21. There were 326 adverse events in the antibody group and 260 in the placebo group. Of these, 19 were treatment-related or procedure-related with antibodies and 41 with placebo. None of the serious events was treatment-related.

What it means for patients

The authors say long-acting antibodies can sustain control of the virus without ART. They say this applies to people treated in early-stage HIV. They call it a step toward ART-free remission.

Why it is not certain yet

The trial had 68 people. They were adults aged 18-60 years who began ART early. The abstract does not give results beyond week 20.

Source

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.